中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | HF554036 |
|---|---|
| 種反応性 | Human |
| アプリケーション | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主種 | Human |
| クローン性 | Monoclonal |
| アイソタイプ | IgG1-kappa |
| 生物学的活性 | NG25 is a potent dual TAK1 and MAP4K2 inhibitor, with IC 50 s of 149 nM and 21.7 nM, respectively. NG25 also potently suppresses several kinases such as LYN, CSK, FER, p38α, ABL,ARG and SRC, with IC 50 s of 12.9, 56.4, 82.3, 102, 75.2, and 113 nM, respectively [1]. NG25 is very potent suppressor of CpG B- or CpG A-stimulated secretion of IFNα and CL097-stimulated secretion of IFNβ, with complete inhibition by 400 nM [2]. NG25 treatment reduces cell viability of all tested breast cancer cell lines in a dose dependent manner. NG25 (2?uM) enhances the cytotoxic effect of Dox on breast cancer cells [3]. |
| 発現システム | Mammalian cells |
| ターゲット | MEGT1, G6D, Megakaryocyte-enhanced gene transcript 1 protein, NG25, LY6G6D, C6orf23, Protein Ly6-D, Lymphocyte antigen 6 complex locus protein G6d, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% purity as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | O95868 & P07766 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 別名 | Bispecific, 2885203-43-8 |
| 参考文献 | 1. Tan L, et al. Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96. [HF554036] 2. Pauls E, et al. Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cells. J Biol Chem. 2012 Jun 1;287(23):19216-28. [HF554036] 3. Wang Z, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016 Sep 7;6:32737. [HF554036] |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
SDS-PAGE for Research Grade Linclatamig
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
